NCT05567458View on ClinicalTrials.gov

A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions
Beta-thalassemia
Interventions
DRUG

Luspatercept

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (10)

510120

Local Institution - 0009, Guangzhou

510515

Local Institution - 0004, Guangzhou

518035

Local Institution - 0005, Shenzhen

525447

Local Institution - 0002, Maoming

530012

Local Institution - 0003, Nanning

530021

Local Institution - 0001, Nanning

545006

Local Institution - 0007, Liuzhou

570203

Local Institution - 0006, Haikou

570311

Local Institution - 0008, Haikou

650032

Local Institution - 0010, Kunming

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05567458 - A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. | Biotech Hunter | Biotech Hunter